MS
AURA icon

Maven Securities’s Aura Biosciences AURA Stock Holding History

Maven Securities’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$335K – 331
2026
Q1 		$335K Buy
+50,000
New +$287K 0.01% 372

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Maven Securities's AURA Position: Q2 2026 in Review

Maven Securities sold out of Aura Biosciences (AURA) in Q2 2026, closing a stake of 50,000 shares — an estimated $335K sold.

Maven Securities first reported a position in AURA in Q1 2026 and held it in 1 quarter. The position peaked at $335K in Q1 2026. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Maven Securities reported no remaining Aura Biosciences position as of Q2 2026 after selling out during the quarter.
  • Maven Securities sold 50,000 Aura Biosciences shares in Q2 2026, an estimated $335K.
  • Maven Securities first reported a position in Aura Biosciences in Q1 2026 and held it in 1 quarter.
  • Maven Securities's Aura Biosciences position peaked at $335K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.